Detalles de la búsqueda
1.
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Lancet
; 403(10422): 147-159, 2024 Jan 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38008109
2.
Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis.
Pediatr Allergy Immunol
; 34(7): e13982, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37492920
3.
Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study.
Allergy
; 77(7): 2175-2184, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34773261
4.
Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System.
Pharmaceutics
; 15(9)2023 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37765235
5.
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
J Clin Oncol
; 36(23): 2395-2404, 2018 08 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29856692
Resultados
1 -
5
de 5
1
Próxima >
>>